ebomi
Colour theme
Sign in
Insider · CIK 0001572451

Bonita David P

CIK 0001572451 Name as filed on the most recent filing

Filed as Bonita David P (34)

86 transaction lines · from 34 filings · filed 2013-05-22 to 2026-04-23 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

86 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2020-09-25 P, Open-market purchase Prelude Therapeutics IncPRLD 2 lines 23,499,200, acquired Open Form 4 filing 0001209191-20-052517
2020-08-10 P, Open-market purchase Acutus Medical, Inc.AFIB 2 lines 7,470,000, acquired Open Form 4 filing 0000950103-20-015725
2020-06-23 P, Open-market purchase Repare Therapeutics Inc.RPTX 2 lines 15,484,000, acquired Open Form 4 filing 0001209191-20-038969
2020-03-12 P, Open-market purchase Imara Inc.IMRA 15,000,000, acquired Open Form 4 filing 0000899243-20-008495
2019-12-11 S, Open-market sale Tricida, Inc.TCDA 60,000,000, disposed Open Form 4 filing 0000947871-19-000960
2019-04-03 P, Open-market purchase Tricida, Inc.TCDA 8,100,000, acquired Open Form 4 filing 0000947871-19-000272
2018-10-19 P, Open-market purchase Si-Bone, Inc.SIBN 3,000,000, acquired Open Form 4 filing 0001209191-18-055700
2018-07-02 P, Open-market purchase Tricida, Inc.TCDA 6,999,999, acquired Open Form 4 filing 0001140361-18-031061
2017-12-08 S, Open-market sale Loxo Oncology, Inc.LOXO 20,625,000, disposed Open Form 4 filing 0000947871-17-000999
2017-11-22 S, Open-market sale Loxo Oncology, Inc.LOXO 20,025,000, disposed Open Form 4 filing 0000947871-17-000970
2017-11-16 S, Open-market sale Loxo Oncology, Inc.LOXO 5 lines 20,051,389, disposed Open Form 4 filing 0000947871-17-000954
2017-01-18 P, Open-market purchase ViewRay, Inc.VRAY 2 lines 991,731, acquired Open Form 4 filing 0000947871-17-000058
2016-08-22 P, Open-market purchase ViewRay, Inc.VRAY 2 lines 3,357,318, acquired Open Form 4 filing 0000947871-16-001452
2016-08-10 S, Open-market sale Loxo Oncology, Inc.LOXO 12,074,225, disposed Open Form 4 filing 0000947871-16-001415
2014-08-06 P, Open-market purchase Loxo Oncology, Inc.LOXO 3,580,005, acquired Open Form 4 filing 0001140361-14-031056
2013-05-23 P, Open-market purchase Ambit Biosciences CorpAMBI 2 lines 87,366, acquired Open Form 4 filing 0001140361-13-022814
2013-05-22 P, Open-market purchase Ambit Biosciences CorpAMBI 2 lines 146,139, acquired Open Form 4 filing 0001140361-13-022814
2013-05-21 P, Open-market purchase Ambit Biosciences CorpAMBI 6 lines 5,350,034, acquired Open Form 4 filing 0001181431-13-029901
2013-05-20 P, Open-market purchase Ambit Biosciences CorpAMBI 2 lines 71,839, acquired Open Form 4 filing 0001181431-13-029901

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 44
  • Open-market sale 42
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Bonita David P, insider transactions. Retrieved 2026-08-25 from https://ebomi.com/insider/0001572451

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.